Ropes & Gray represented the underwriters in Insmed Inc.’s $750 million follow-on offering. The offering was announced in a June 11 press release and closed on June 13.
Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease.
The team was led by capital markets partner Tom Danielski, and included life sciences & regulatory compliance partner Kellie Combs and IP transactions partner Melissa Rones.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.